Promotion of hypertension and end-organ injury by Interleukin 17A mediated by Aldosterone-MR and ENaC

Sai Sindhu Thangaraj

Research output: Thesis › Ph.D. thesis

139 Downloads (Pure)

3 Journal article

3 results

2022
Interleukin 17A infusion has no acute or long-term hypertensive action in conscious unrestrained male mice
Thangaraj, S. S., Enggaard, C., Stubbe, J., Palarasah, Y., Hansen, P. B. L., Svenningsen, P. & Jensen, B. L., Jul 2022, In: Pflügers Archiv - European Journal of Physiology. 474, 7, p. 709-719
Research output: Contribution to journal › Journal article › Research › peer-review
Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients
Thangaraj, S. S., Thiesson, H. C., Svenningsen, P., Stubbe, J., Palarasah, Y., Bistrup, C., Jensen, B. L. & Mortensen, L. A., Feb 2022, In: American Journal of Physiology: Renal Physiology. 322, 2, p. F138-F149
Research output: Contribution to journal › Journal article › Research › peer-review

Open Access
File
115 Downloads (Pure)
The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension
Thangaraj, S. S., Oxlund, C. S., Fonseca, M. P. D., Svenningsen, P., Stubbe, J., Palarasah, Y., Ketelhuth, D. F. J., Jacobsen, I. A. & Jensen, B. L., 1. Jan 2022, In: Journal of Hypertension. 40, 1, p. 153-162
Research output: Contribution to journal › Journal article › Research › peer-review